Grittgene Therapeutics

GrittGene Therapeutics is a preclinical biotechnology company developing innovative therapies for rare neuromuscular diseases, with an initial focus on myotonic dystrophy type 2 (DM2). The company integrates personalized regenerative cell therapy, advanced multi-omics analysis, and next-generation diagnostics to identify disease mechanisms and accelerate the development of targeted, patient-centered treatments. GrittGene is committed to bridging cutting-edge science with real-world clinical impact for underserved rare disease communities.

Therapeutic Developer